|
Re: Add one to the list
|
3
|
Zenith Epigenetics
|
Sep 13, 2023 11:47AM
|
|
NCT05372640
|
4
|
Zenith Epigenetics
|
Sep 12, 2023 11:47AM
|
|
Add one to the list
|
4
|
Zenith Epigenetics
|
Sep 12, 2023 11:35AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
8
|
Resverlogix Corp.
|
Aug 29, 2023 11:13AM
|
|
AGM Oct 26, 2023
|
|
Zenith Epigenetics
|
Aug 11, 2023 03:29PM
|
|
Re: New SEDAR page
|
3
|
Zenith Epigenetics
|
Aug 03, 2023 11:47AM
|
|
New SEDAR page
|
4
|
Zenith Epigenetics
|
Aug 02, 2023 02:29PM
|
|
Re: TNBC no longer active?
|
3
|
Zenith Epigenetics
|
Jun 29, 2023 03:19PM
|
|
Re: TNBC no longer active?
|
4
|
Zenith Epigenetics
|
Jun 29, 2023 11:24AM
|
|
Re: TNBC no longer active?
|
3
|
Zenith Epigenetics
|
Jun 28, 2023 12:37PM
|
|
Re: Zenith Royalties
|
2
|
Resverlogix Corp.
|
Jun 27, 2023 05:10PM
|
|
TNBC no longer active?
|
4
|
Zenith Epigenetics
|
Jun 27, 2023 05:05PM
|
|
Re: What's the deal with Zenith?
|
|
Zenith Epigenetics
|
Jun 22, 2023 03:49PM
|
|
Re: Zenith Royalties
|
1
|
Resverlogix Corp.
|
Jun 22, 2023 02:14PM
|
|
Re: Link to 2023 AGM presentation is up
|
7
|
Resverlogix Corp.
|
Jun 21, 2023 02:07PM
|
|
Link to 2023 AGM presentation is up
|
2
|
Resverlogix Corp.
|
Jun 21, 2023 01:22PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
2
|
Resverlogix Corp.
|
Jun 13, 2023 12:32PM
|
|
Re: Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma
|
2
|
Zenith Epigenetics
|
Jun 01, 2023 07:24PM
|
|
New Phase 1 NCI trial
|
7
|
Zenith Epigenetics
|
May 24, 2023 05:43PM
|
|
Re: IR - "but all I can tell you at the moment is that we believe we are making real progress towards achieving our goals."
|
6
|
Resverlogix Corp.
|
May 11, 2023 03:17PM
|
